PTK7 and colorectal carcinoma: Early results from a phase I trial indicated that this therapy was well tolerated in patients with advanced epithelial cancers, including CRC, without dose-limiting toxicities or severe immune-related adverse events such as GvHD.32 Another approach involves allogeneic anti–protein tyrosine kinase 7 (PTK7) CAR-T cells, which target PTK7, a molecule highly expressed in several solid tumors, including CRC.